BioCardia, Inc.
BCDAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, BioCardia, Inc. focuses on Biotechnology services and products. BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. At a $14.1M market cap, BioCardia, Inc. ranks as a micro-cap company within healthcare. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Market Cap
$14.1M
Beta
0.62
P/E (TTM)
—
P/E (Fwd)
-1.60
EPS (TTM)
$-0.61
EPS (Fwd)
$-0.58
ROE
-1803.2%
ROA
-135.0%
Cash
$4.1M
Total Debt
$293,000
Free CF
-$5.7M
52W Change
-33.6%
Annual Financials
Cash vs Debt
Where BCDA stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, BCDA finished 0.95% below its 150-day moving average ($1.05) and 5.45% below its 200-day moving average ($1.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BCDA overbought or oversold?
At the October 12, 2026 close, BCDA's RSI(14) was 43.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
BioCardia, Inc. holds $4.1M in cash against $293K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$5.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -1803.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $1.4M (2022) to $0 (2025), a 100% decline worth watching.
The relatively low beta of 0.62 suggests BCDA is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, BCDA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioCardia, Inc. and its sector.